GTC Biotherapeutics (fka GTCB)

[Cincinnatus]

Expectations for these two executives?

http://www.gtc-bio.com/pressreleases/pr040307.html


FRAMINGHAM, MA - April 3, 2007 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today the expansion of its capabilities in business and commercial development. Ashley Lawton, Ph.D., GTC's new Vice President of Business Development, will focus primarily on additional strategic partnering for our proprietary programs, including monoclonal antibodies, as well as developing partners for follow-on biologics. Rick Finnegan, GTC's new Vice President of Commercial Development, will focus on market introduction strategies for our products, including through partners.

It seems that it would be reasonable to expect SOME achievements from these two during a 6-9 month time period. That would be sometime before 2008.

Is this reasonable? Anyone want to speculate about their priorities?